Stockreport

Disc Medicine: Downgrading As CRL Puts APOLLO Study Into Question [Seeking Alpha]

Disc Medicine, Inc.  (IRON) 
PDF The FDA requires phase 3 APOLLO data before reconsidering bitopertin approval, delaying any decision until at least mid-2027. IRON's pipeline includes DISC-0974 for m [Read more]